NYSE:ANRO Alto Neuroscience (ANRO) Stock Price, News & Analysis $14.36 -0.13 (-0.90%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$14.23▼$14.7450-Day Range$9.85▼$16.2952-Week Range$9.40▼$24.00Volume74,699 shsAverage Volume178,113 shsMarket Capitalization$386.00 millionP/E RatioN/ADividend YieldN/APrice Target$35.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Alto Neuroscience alerts: Email Address Alto Neuroscience MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside143.7% Upside$35.00 Price TargetShort InterestBearish15.48% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 3 Articles This WeekInsider TradingAcquiring Shares$152,069 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.93) to ($3.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.00 out of 5 starsMedical Sector826th out of 936 stocksPharmaceutical Preparations Industry385th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAlto Neuroscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAlto Neuroscience has only been the subject of 2 research reports in the past 90 days.Read more about Alto Neuroscience's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.48% of the float of Alto Neuroscience has been sold short.Short Interest Ratio / Days to CoverAlto Neuroscience has a short interest ratio ("days to cover") of 27.4, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldAlto Neuroscience does not currently pay a dividend.Dividend GrowthAlto Neuroscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANRO. Previous Next 2.3 News and Social Media Coverage News SentimentAlto Neuroscience has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Alto Neuroscience this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ANRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Alto Neuroscience to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alto Neuroscience insiders have bought more of their company's stock than they have sold. Specifically, they have bought $152,069.00 in company stock and sold $0.00 in company stock.Read more about Alto Neuroscience's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alto Neuroscience are expected to decrease in the coming year, from ($2.93) to ($3.16) per share.Read more about Alto Neuroscience's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Alto Neuroscience Stock (NYSE:ANRO)Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Read More ANRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANRO Stock News HeadlinesJuly 12, 2024 | insidertrades.comAlto Neuroscience, Inc. (NYSE:ANRO) Insider Adam Savitz Purchases 12,069 SharesJuly 26 at 1:08 AM | americanbankingnews.comAlto Neuroscience, Inc.'s Lock-Up Period Will Expire on July 31st (NYSE:ANRO)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 16, 2024 | americanbankingnews.comAlto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Buy" from AnalystsJune 20, 2024 | businesswire.comAlto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with SchizophreniaJune 18, 2024 | businesswire.comAmit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award WinnerJune 10, 2024 | investorplace.comWake Up! 3 Lesser-Known Stocks Investors Are Sleeping OnMay 29, 2024 | finance.yahoo.comAlto Neuroscience to Present at the Jefferies Global Healthcare ConferenceJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 21, 2024 | businesswire.comAlto Neuroscience Appoints Michael Hanley as Chief Operating OfficerMay 16, 2024 | markets.businessinsider.comBuy Rating for Alto Neuroscience: Promising Trials in MDD and Advances in CIAS TreatmentMay 16, 2024 | bloomberg.comAlto Aims to Redefine Psychiatry Landscape: Vanguards of Health CareMay 14, 2024 | msn.comANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024May 14, 2024 | finance.yahoo.comAlto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | finance.yahoo.comAlto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific ConferencesApril 23, 2024 | markets.businessinsider.comTreatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry LandscapeApril 23, 2024 | businesswire.comAlto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for SchizophreniaApril 3, 2024 | finance.yahoo.comAlto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive DisorderSee More Headlines Receive ANRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ANRO Previous SymbolNYSE:ANRO CUSIPN/A CIK1999480 Webwww.altoneuroscience.com Phone(650) 200-0412FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$43.00 Low Stock Price Target$32.00 Potential Upside/Downside+143.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.05 Current Ratio26.02 Quick Ratio26.02 Sales & Book Value Annual Sales$210,000.00 Price / Sales1,836.80 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares26,880,000Free FloatN/AMarket Cap$385.73 million OptionableN/A BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Amit Etkin M.D. (Age 47)Ph.D., Founder, Chairman of the Board, CEO & President Comp: $705.65kMr. Nicholas C. Smith (Age 35)CFO & Secretary Comp: $624.12kMr. Adam Savitz M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $579.57kMs. Melissa Berman (Age 44)Vice President of Finance & Accounting Ms. Erin R. McQuade J.D. (Age 49)General Counsel & Chief Administrative Officer Ms. Jessica Powell (Age 49)Chief Development Officer Mr. Fadi Abdel M.D. (Age 45)Senior Vice President of Innovation More ExecutivesKey CompetitorsKura OncologyNASDAQ:KURASchrödingerNASDAQ:SDGRAvadel PharmaceuticalsNASDAQ:AVDLMannKindNASDAQ:MNKDKiniksa PharmaceuticalsNASDAQ:KNSAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 23,557 shares on 7/26/2024Ownership: 0.088%Adam SavitzBought 12,069 shares on 7/9/2024Total: $152,069.40 ($12.60/share)RA Capital Management L.P.Bought 1,385,491 shares on 5/17/2024Ownership: 5.154%Artal Group S.A.Bought 350,000 shares on 5/17/2024Ownership: 1.302%Zimmer Partners LPBought 75,000 shares on 5/17/2024Ownership: 0.279%View All Insider TransactionsView All Institutional Transactions ANRO Stock Analysis - Frequently Asked Questions How have ANRO shares performed this year? Alto Neuroscience's stock was trading at $21.80 at the beginning of the year. Since then, ANRO stock has decreased by 34.1% and is now trading at $14.36. View the best growth stocks for 2024 here. How were Alto Neuroscience's earnings last quarter? Alto Neuroscience, Inc. (NYSE:ANRO) released its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.30. When did Alto Neuroscience IPO? Alto Neuroscience (ANRO) raised $129 million in an initial public offering on Friday, February 2nd 2024. The company issued 8,040,000 shares at $16.00 per share. When does Alto Neuroscience's lock-up period expire? Alto Neuroscience's lock-up period expires on Wednesday, July 31st. Alto Neuroscience had issued 8,040,000 shares in its public offering on February 2nd. The total size of the offering was $128,640,000 based on an initial share price of $16.00. After the end of Alto Neuroscience's lock-up period, company insiders and major shareholders will be able to sell their shares of the company. Who are Alto Neuroscience's major shareholders? Top institutional investors of Alto Neuroscience include Bank of New York Mellon Corp (0.09%). Insiders that own company stock include Wave Global Lp Alpha, Adam Savitz and Nicholas Conrad Smith. View institutional ownership trends. How do I buy shares of Alto Neuroscience? Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ANRO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
